Skip to content

King Pharmaceuticals KG Discontinued Ops Cash Flow

Discontinued Ops Cash Flow at other companies

Tiptree Inc. logo
Tiptree Inc.TIPT

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's discontinued ops cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's discontinued ops cash flow?
King Pharmaceuticals (KG) reported discontinued ops cash flow of -$703.25K in Q4 2025.
What does discontinued ops cash flow mean?
Represents the net cash flow generated by or used in business units that have been divested or are held for sale. This metric isolates the impact of non-core or discontinued operations from the ongoing cash generation of the primary business. It is essential for investors to distinguish between recurring operational cash flows and one-time impacts from business exits.